Twist Bioscience (TWST) Capital Expenditures (2017 - 2026)

Twist Bioscience (TWST) has reported Capital Expenditures for 10 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures rose 564.11% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $5.8 million (up 580.68% YoY), while the FY2025 annual figure was $1.6 million, up 463.81% from the prior year.
• Capital Expenditures improved to $4.4 million in Q1 2026 per TWST's latest filing, from $1.2 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $48.0 million in Q1 2022 and bottomed at -$10.1 million in Q1 2023.
• Historically, Capital Expenditures has averaged $8.2 million across 5 years, with a median of $2.3 million in 2024.
• Annual changes were most pronounced in 2022 — Capital Expenditures jumped 32765.75% — and 2025, when it plunged 369.05%.
• Twist Bioscience's Capital Expenditures stood at $11.8 million in 2022, then sank by 102.54% to -$300000.0 in 2023, then jumped by 856.0% to $2.3 million in 2024, then plunged by 47.88% to $1.2 million in 2025, then soared by 268.7% to $4.4 million in 2026.
• Business Quant data shows TWST's Capital Expenditures at $4.4 million in Q1 2026, $1.2 million in Q4 2025, and $965000.0 in Q3 2025.